Esperion prices $85.1M public offering of 56.7M shares at $1.50; underwriters fully exercise option

Esperion Therapeutics, Inc.

Offering of 56,700,000 shares priced at $1.50 per share; gross proceeds ~$85.1M.
Underwriters fully exercised option for additional 8,505,000 shares at same price.
Net proceeds expected to be ~$90.8M after underwriting discount and expenses.
Closing expected Jan 23, 2024; Jefferies LLC sole book-running manager.
Proceeds to fund commercialization of NEXLETOL/NEXLIZET, R&D, and working capital.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Esperion Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC (effective 2024-01-18).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC
Effective: 2024-01-18

Exact text from the filing

On January 18, 2024, Esperion Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC (“Jefferies”), as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 56,700,000 shares of common stock of the Company, par value $0.001 per share (“Common Stock”), at a purchase price to the public of $1.50 per share.

View on SEC.gov

Browse all material agreements →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-005351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.